A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Public ClinicalTrials.gov record NCT05259917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients
Study identification
- NCT ID
- NCT05259917
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2022 (Actual)
- Primary completion
- Dec 31, 2023 (Actual)
- Completion
- Dec 31, 2023 (Actual)
- Last update posted
- May 2, 2025
2022 – 2023
United States locations
- U.S. sites
- 22
- U.S. states
- 19
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| KalVista Investigative Site | Birmingham | Alabama | 35209 | — |
| KalVista Investigative Site | Scottsdale | Arizona | 85251 | — |
| KalVista Investigative Site | Little Rock | Arkansas | 72205 | — |
| KalVista Investigative Site | San Diego | California | 92122 | — |
| KalVista Investigative Site | San Diego | California | 92123 | — |
| KalVista Investigative Site | Santa Monica | California | 90404 | — |
| KalVista Investigative Site | Centennial | Colorado | 80112 | — |
| KalVista Investigative Site | Colorado Springs | Colorado | 80907 | — |
| KalVista Investigative Site | Tampa | Florida | 33613 | — |
| KalVista Investigative Site | Chicago | Illinois | 60612 | — |
| KalVista Investigative Site | Overland Park | Kansas | 66211 | — |
| KalVista Investigative Site | Louisville | Kentucky | 40215 | — |
| KalVista Investigative Site | Chevy Chase | Maryland | 20815 | — |
| KalVista Investigative Site | Plymouth | Minnesota | 55446 | — |
| KalVista Investigative Site | St Louis | Missouri | 61414 | — |
| KalVista Investigative Site | New York | New York | 10029 | — |
| KalVista Investigative Site | Charlotte | North Carolina | 28277 | — |
| KalVista Investigative Site | Toledo | Ohio | 43617 | — |
| KalVista Investigative Site | Hershey | Pennsylvania | 17033 | — |
| KalVista Investigative Site | Dallas | Texas | 75231 | — |
| KalVista Investigative Site | Layton | Utah | 84041 | — |
| KalVista Investigative Site | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05259917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05259917 live on ClinicalTrials.gov.